• Explore /
  • Poster
  • / Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.

Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.

Abstract Poster

Authors

Susanna Ulahannan

Susanna Varkey Ulahannan

University of Okahoma Health Sciences Center, Oklahoma City, OK

Susanna Varkey Ulahannan , Thomas Urban Marron , Haeseong Park , John M. Kaczmar , Ryan D. Stephenson , Nehal J. Lakhani , Greg Andrew Durm , Jaspreet Singh Grewal , Anthony B. El-Khoueiry , Jason J. Luke , Courtney Beers , Swaminathan Murugappan , Patricia LoRusso , Douglas Adkins , J. Randolph Hecht

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT04485013

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 2524)

DOI

10.1200/JCO.2024.42.16_suppl.2524

Abstract #

2524

Poster Bd #

3

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.

Interim safety and efficacy results from a phase 1 study of NT219 in adults with advanced solid tumors.

First Author: Alberto Bessudo

First Author: Antoine Hollebecque

First Author: Katharine Andress Rowe Price

First Author: Susanna Varkey Ulahannan